share_log

宣泰医药(688247.SH):产品达格列净二甲双胍缓释片获得药品注册证书

Xuantai Pharmaceutical (688247.SH): The product Dapagliflozin Metformin SR Tablets has obtained the pharmaceutical registration certificate.

Gelonghui Finance ·  Sep 18 03:41

On September 18, GeLongHui announced that XuanTai Pharmaceutical (688247.SH) has received official approval for its generic version of Dapagliflozin and Metformin Hydrochloride Sustained-release Tablets, making it the first domestically approved generic pharmaceutical for this type of medication in China. The approved Dapagliflozin and Metformin Hydrochloride Sustained-release Tablets, used to treat type 2 diabetes, were developed by AstraZeneca and were launched in China in June 2023. They are included in the National Medical Insurance Category B for reimbursement.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment